Novacyt eyes M&A as it names corporate development officer

Novacyt, AIM’s star performer of last year has reshuffled its finance executives and exec management as it looks to continue its growth trajectory this year.

In an update to the market, the international diagnostics business revealed that it has hired a new Chief Financial Officer, while its existing Chief Financial Officer will move into a more strategic role as Chief Corporate Development Officer.

James McCarthy will be the new CFO, joining from Flint Group, while current CFO Anthony Dyer will become the new Chief Corporate Development Officer – a role that is traditionally synonymous with mergers and acquisitions.

Commenting on the appointments was Novacyt CEO Graham Mullis who noted:

I would also like to take this opportunity to thank Anthony personally for the key role he has played in helping transform Novacyt into a leading diagnostics developer and manufacturer. His new, important role reflects the Company’s growth strategy, which includes selective potential M&A to supplement organic growth initiatives. I look forward to working with Anthony and James as part of an expanded executive team.”

The Novacyt share price is currently at 855p.

McCarthy will become a board member.

Daily Movers

Let's Talk

Buying Abingdon Health shares - w …Great interview - thanks. Prospects look good and not definitely n … Read More
Holding or selling ODX shares? Pr …That update looks like it saved it up from 40p! Would look foolish … Read More
Does Aquis do RNS announcements£270 per announcement that's mad!??! Would definitely make se … Read More
Buying Tremor SharesNot the end of the world; £8 now so not the best short term gain Read More
BOTB share price target at £14 - …Haven't seen the report but suppose if they invest wisely and … Read More
Hey, profit awaits! Free Sharebuyers Newsletter

Receive hot tips you can profit from - only sent when it matters. Twitter: @ShareBuyers.